Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | XBP1 | P17861 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485323 | 0.80 | ALDH1A1 (0.49) | LMNAGAASMN1; SMN2MAPTXBP1 | |
| SCHEMBL3964774 | 0.79 | MAPT (0.82) | LMNAGAASMN1; SMN2MAPTXBP1 | |
| SCHEMBL3959067 | 0.79 | MAPT (0.80) | GAASMN1; SMN2MAPTXBP1HTT | |
| SCHEMBL1643497 | 0.77 | MAPT (0.61) | LMNAGAASMN1; SMN2MAPTXBP1 | |
| SCHEMBL27764417 | 0.76 | MAPT (0.83) | MAPTXBP1HTTKMT2AMEN1 | |
| SCHEMBL4009897 | 0.76 | CNR1 (0.65) | LMNASMN1; SMN2MAPTXBP1HTT | |
| SCHEMBL3484973 | 0.76 | CACNA1B (0.59) | RORC | |
| SCHEMBL4012507 | 0.75 | MAPT (0.72) | GAASMN1; SMN2MAPTXBP1HTT | |
| SCHEMBL3485481 | 0.75 | CACNA1B (0.54) | ALDH1A1RORC | |
| SCHEMBL12310740 | 0.74 | ALDH1A1 (0.63) | LMNAGAASMN1; SMN2HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399486-B2 | Benzenesulfonyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-03-19 | — | — | US | claimed |
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2011-04-28 | — | — | US | claimed |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-03-11 | — | — | US | claimed |
| WO-2008124118-A1 | BENZENESULFONYL COMPOUNDS AND THE USE THEROF | PURDUE PHARMA L.P. (DE) | 2008-10-16 | — | — | WO | claimed |
| US-8399486-B2 | Benzenesulfonyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399486-B2 | Benzenesulfonyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399486-B2 | Benzenesulfonyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2008124118-A1 | BENZENESULFONYL COMPOUNDS AND THE USE THEROF | PURDUE PHARMA L.P. (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124118-A1 | BENZENESULFONYL COMPOUNDS AND THE USE THEROF | PURDUE PHARMA L.P. (DE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | CACNA1A, CACNA1I, TRPV1 | LMNA 1564/4885GAA 2359/4885SMN1; SMN2 569/4885 |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | CACNA1A, CACNA1I, TRPV1 | LMNA 1564/4885GAA 2359/4885SMN1; SMN2 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.